One way of introducing the concept of quality management in clinical transfusion is to consider some questions that any patient might ask if they believe that a transfusion may be given.
Here are some examples:
With these questions, the patient is seeking some evidence that the hospital does a good job in providing blood transfusions.
One way that the hospital can give reassurance is by providing evidence that things are done correctly. This could be information about training, documentation of procedures, or results of checks of performance or comparisons of results between one hospital and others. All these are important parts of a quality system. (11234582)
This Manual provides practical guidance that can help to provide answers to questions of this type, whether they are asked by patients or, in different ways, by quality inspectors, auditors or regulators.
Many studies show that patients suffer avoidable harm due to errors and accidents (quality failures) in hospitals. These occur in many aspects of the process of care. For most patients and their clinicians, transfusion is only one element of the whole process of care and transfusion risks are only a small proportion of all the risks to which patients are exposed. For these reasons a quality management system for transfusion should be planned as part of a hospital’s wider quality system. This was a key conclusion of the 2009 Wildbad-Kreuth Symposium.
Quality systems have developed largely in relation to manufacturing processes. The same broad principles apply to the clinical setting. However some of the vocabulary, concepts and methods used by quality experts are unfamiliar to many clinicians and also they may not apply directly to the clinical context.
For this reason we have used simple and non-specialist terms where possible. Relevant extracts from the EU directives are shown throughout the text. One relevant definition of clinical quality assurance is:
“Improving performance and preventing problems, through planned and systematic activities including documentation, training and review.”
Changes in procedures are introduced in a controlled fashion and proper records are maintained
A key success factor can be leadership provided by a respected senior clinician who develops an active professional interest in improving transfusion treatment. ‘Clinical Champions’ for good transfusion may emerge from specialties such as anaesthetics/ intensive care, surgery or haematology, where transfusion is frequently utilised. One approach that has been successful is to engage such specialists in collaborative programmes of clinical audit or research on the use of transfusion in their own specialist field.
An effective and well-led Hospital Transfusion Committee (HTC) or a body with equivalent functions is widely held to be essential for improvement of clinical transfusion practice. The primary aim should be to promote a high standard of care for patients at risk of transfusion (i.e. those who must be transfused, and also those who, with good clinical management, may avoid the need for transfusion). The HTC should have a clear line of accountability to an appropriate post at a senior management level in the institution. The HTC should have the authority to determine hospital policy in relation to blood transfusion and must have an effective means of disseminating it to all relevant staff and to patients where appropriate. (www.transfusionguidelines.org.uk)
Should include the following:
The HTC should include clinicians from specialties in the hospital that utilise transfusion, for example haematology, anaesthetics, intensive care, surgery, or obstetrics, as well as staff from nursing, blood bank and audit or research departments. The committee requires an effective chairperson who has the professional respect of senior medical personnel and can command the attention of hospital management.
The HTC should meet regularly, have a formal agenda and keep full records of its decisions. It must have the authority and support to ensure that its decisions are effectively communicated to and followed by staff who contribute to the clinical transfusion process.
The transfusion committee may make excellent recommendations, but it needs an executive officer, a person who is employed specifically to ensure that the recommendations are converted into actions. Several countries have created a new position for this purpose. The manual uses the term Transfusion Practitioner (TP) (www.betterblood.org.uk) but posts with similar responsibilities have also been given titles such as Transfusion Safety Officer (TSO), Transfusion Nurse Coordinator (TNC) or Haemovigilance Officer (www.transfusionsafety.ca). The TP is concerned with the clinical transfusion process, ”taking quality assurance from the blood bank to the patient”. The transfusion practitioner’s job description would typically specify responsibilities such as these:
In many countries the TP have a background in nursing or the transfusion laboratory; other countries have employed doctors or pharmacists in similar roles. The goal should be for the TP to be part of a wider transfusion team that should develop with the encouragement and motivation of the transfusion committee. In several EU countries, the TP role is now viewed as an essential part of the hospital’s quality improvement programme in transfusion.
The Departments of Health in the UK have recommended that hospitals have a Hospital Transfusion Team (HTT) to manage the day-to-day business of blood transfusion within the hospital. Membership should include a medical transfusion specialist, the head of the blood bank and the transfusion practitioner.
Success in creating change and improvement depends on factors other than the scientific or technical. It is important to be aware of the many influences on the ability to make change happen. Awareness of pressures such as those illustrated in Figure 3.1 can improve the ability to influence decisions and actions. Research also shows the importance of a better understanding of psychological and behavioural factors that underlie the behaviours of health care professionals.
Evaluation of the clinical use of blood products is often done by monitoring or surveying clinical practice against objective indicators of performance. This is perhaps better described as benchmarking than audit. Useful indicators of practice (quality or performance indicators) must be easy to collect and quantifiable.
Quality indicators may be used to monitor and evaluate the quality of the therapeutic transfusion process or compliance with clinical guidelines. There are two types of indicators: internal and external.
Internal indicators are used for quality management and improvement of the clinical transfusion process within an institution. They must be relevant for the critical steps in the process and the professionals involved. They must be specific and detailed, easy to sample, educative and effective in stimulating actions for improvement.
External indicators provide information for external control agencies such as health care inspectorate and/or for comparison between hospitals (benchmarking). These have to provide monitoring or signaling information about the quality of the process, measure global aspects such as global outcome and require good validation. According to what they measure three types of indicators can be described:
Structure indicators: How well have I organised the process?
Process indicators: Am I doing well?
Outcome indicators: Do I reach the result required?
Indicators are only one tool for evaluating practice. In some cases audit may provide better information. However, if used in the right way indicators may be an efficient and tool for improving the quality of the therapeutic transfusion process.
The following list is a practical example from the Leiden University Hospital in the Netherlands, where indicators are sampled annually and reviewed by the Hospital Transfusion Committee. This identifies priorities and sets targets for evaluation.
The number of expired products in the stock of the hospital blood bank divided by the total number of blood products in the stock of the hospital blood bank.
The number of units of blood components (red cells, platelets and fresh frozen plasma) that are not prescribed according to the known guidelines, divided by the number of prescriptions for blood products (red cells, FFP, platelets) in the same period.
The number of blood components (red cells, platelets and fresh frozen plasma) returned to the hospital blood bank by a department, divided by the total number of blood components supplied by the blood bank service to that department.
The number of blood components that are not transfused divided by the number obtained from the blood establishment.
The number of blood product request forms lacking essential data divided by the total number of orders for blood components in the same period.
The number of detected discrepancies in ABO and RhD typing of patients due to identification or labeling errors outside the transfusion laboratory divided by the total number of patient samples tested for ABO and RhD type screenings in the same period.
The number of detected discrepancies in ABO and RhD screening of patients due to errors in the transfusion laboratory divided by the total number of ABO and RhD type screenings performed in the same period.
The number of units for which there is no record in the hospital blood bank or blood establishment of the final destination (transfused to an identified patient, destroyed or returned to the BE) divided by the number of units issued by the HBB or BE.